We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Retinal Imaging Detects Changes Associated with Alzheimer's Disease

By MedImaging International staff writers
Posted on 23 Jul 2014
Print article
Image: Amyloid plaques showing up in retinal scan as fluorescent spots as curcumin binds to them (Photo courtesy of CSIRO).
Image: Amyloid plaques showing up in retinal scan as fluorescent spots as curcumin binds to them (Photo courtesy of CSIRO).
A noninvasive optical imaging device can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease (AD), according to a new study.

Researchers at the Commonwealth Scientific and Industrial Research Organization (CSIRO, Melbourne, Australia) conducted a study to measure retinal beta-amyloid plaque in 40 volunteers, using a fluorescence-based scan that was compared to the results of brain positron emission tomography (PET) scans using the Pittsburgh Compound B (PiB) amyloid tracer. The researchers used orally administered curcumin as a tracer, on the basis of previous research indicating that it binds beta-amyloid protein with high affinity.

The researchers found that besides correlating strongly with plaque burden estimates from PiB-based PET scans, the retinal scans distinguished patients with AD from other participants with 100% sensitivity and a specificity of 80.6%. For the study, the researchers used the NeuroVision system, a product of NeuroVision Imaging (Sacramento, CA, USA), which provides a count of beta-amyloid plaques in the retina, their two-dimensional (2D) extent in square microns, and their distribution. All three parameters are combined into a "retinal amyloid index" to provide a single-number estimate of beta-amyloid plaque burden.

The Australian study is one of several in progress to determine if similar results can be confirmed in humans living with the disease. The study involves a total of 220 patients composed of diagnosed with AD, including a group with mild cognitive impairment, another group of people with no evidence of brain abnormality, and controls. The study was presented at the Alzheimer's Association International Conference, held during July 2014 in Copenhagen (Denmark).

“All people with the disease tested positive and most of the people without the disease tested negative,” said lead author and study presenter Shaun Frost, MSc, BSc, a biomedical scientist at CSIRO. “The optical imaging exam appears to detect changes that occur 15–20 years before clinical diagnosis. It's a practical exam that could allow testing of new therapies at an earlier stage, increasing our chances of altering the course of Alzheimer's disease.”

“PET scans require the use of radioactive tracers, and cerebrospinal fluid analysis requires that patients undergo invasive and often painful lumbar punctures,” said Prof. Keith Black, MD, chair of the department of neurosurgery at Cedars-Sinai Hospital (Los Angeles, CA, USA), who helped develop the NeuroVision system. “The retina, unlike other structures of the eye, is part of the central nervous system, sharing many characteristics of the brain. By staining the plaque with curcumin […] we could detect it in the retina even before it began to accumulate in the brain.”

Curcumin, a major component of the yellow Indian spice turmeric, has fluorescent properties, and is also believed to have a variety of medicinal qualities.

Related Links:
Commonwealth Scientific and Industrial Research Organization
NeuroVision Imaging


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Compact C-Arm with FPD
Arcovis DRF-C R21
New
Computed Tomography (CT) Scanner
Aquilion Serve SP
Dose Area Product Meter
VacuDAP

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.